How can biopharma companies access non-dilutive capital to make the most of growth and strategic opportunities?
Royalty monetization and revenue interest financing offer a growing number of biopharma companies attractive alternatives to traditional financing strategies. These transactions historically are tailored to meet a company's specific capital needs without the dilution associated with equity financings, the limitations imposed by covenants by commercial debt, or the loss of value often associated with collaboration partnerships. And in today’s market they can also be employed as acquisition financing or as a third party financing strategy to extract maximum value out of a large pharma collaboration by reducing their balance sheet risk.
Hear from an experienced panel comprising senior executives from healthcare investors HealthCare Royalty Partners and OrbiMed Advisors, pharma company Progenics Pharmaceuticals and corporate finance advisory boutique firm Torreya Partners in addition to corporate and finance partners at Dechert LLP on how to put royalty monetization and revenue interest financing to work in achieving your financing and strategic objectives.
View the presentation here »
Click here for a transcript of the discussion »
Related Professionals
